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Sometimes, truth may be stranger than fiction
Abstract
Coronary heart disease (CHD) represents an important problem worldwide. At present, more 
women than men are evaluated for CHD and it has been recognized that the prevalence of this 
pathology in women is at least the same as in men. We have learned that cardiac syndrome X 
(CSX) is frequent because worldwide each year millions of people (mostly women) with angina 
pectoris without flow-limiting epicardial pathology are identified. Data from large myocardial 
infarction registries suggest a 5% to 25% prevalence of cases without flow-limiting coronary 
pathology. It must, however, be considered that these people are said to have normal coronary 
arteries by visual analysis of biplane coronarography. On the other hand, as demonstrated 
from autopsy, and in vivo by ultrasound intravascular studies, it would be more appropriate 
to say that in the majority of these cases no obstructive or flow-limiting coronary pathology was 
detected by coronarography. In CSX, endothelial dysfunction and microvascular dysfunction, 
sometimes with coronary microvascular spams and epicardial coronary artery spasm, have 
been recognized as pathophysiologic mechanisms. In CSX, symptoms and pathologic signs 
are the same in patients with flow-limiting coronary pathology. The difference lies in the fact 
that the mechanisms of myocardial ischemia are microvascular and flow-limiting epicardial 
coronary pathology is absent. By interplay, the pathologic entities at work in CSX are linked 
with poor long-term outcome. The prevalence of these outcomes is probably smaller than in 
patients with flow-limiting coronary pathology but we lack precise values. Nonetheless, severe 
cardiovascular complications are frequent in CSX and it is thus the pathology is not benign. 
Drugs used in coronary ischemic disease are empirically prescribed to treat CSX, but we lack 
data from specific trials. It seems that statins and ranolazine might exert positive effects. How-
ever, specific research to target interventions in CSX would be necessary. (Cardiol J 2015; 22, 
6: 605–612)
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Introduction
Coronary heart disease (CHD) represents 
an important medical problem worldwide, whose 
prevalence is augmenting, especially due to 
the growingly ageing populations in the west-
ern countries and to the increasing changes in 
smoking and diet in the developing countries. As 
a result, the number of cardiac interventions is 
expected to increase further over the coming 
decades, reaching more than a million of annual 
procedures worldwide in the next years. In the 
past there was a strong bias in evaluating women 
with angina pectoris (AP). However, at present 
coronarography (CAG) is rapidly performed in 
women with suspected CHD and it is proven that 
CHD is at least as frequent in women as in men. 
Typical AP is a cardinal symptom of CHD and meets 
all of the following criteria: retrosternal chest 
discomfort of characteristic quality and duration; 
provoked by exertional or emotional stress; re-
lieved by rest and/or nitrates within minutes [1, 2]. 
In 1940, it was stated [3] that no patients with 
AP failed to show occlusion in at least one of the 
major coronary arteries and flow-limiting coronary 
stenosis causing ischemia was accepted as the etio-
logic cause of AP and CHD. However, it was soon 
realized that this assumption was not unconditional 
because AP may also occur in other diseases, such 
as e.g. hypertrophic cardiomyopathy, severe aortic 
stenosis, profound anemia, and carboxyhemoglobin 
intoxication. In 1967, 2 papers [4, 5] described 
patients with typical AP, sometimes dyspnea and 
other neuro-vegetative symptoms (e.g. perspira-
tion, tachycardia and dizziness) without epicardial 
coronary artery pathology. This pathology is not 
rare and is often termed ‘cardiac syndrome X’ 
(CSX) [6–10].
A typical patient with CSX
A 53-year-old Caucasian woman with a weight 
of 65 kg had stable typical AP, which was questiona-
bly relieved by sublingual nitroglycerin. Her father 
died at the age of 55 years because of myocardial 
infarction. The patient had no other cardiovascular 
risk factors. The resting electrocardiogram (ECG) 
showed ischemic changes (Fig. 1). Plasma levels 
of troponin, measured during and several hours 
after episodes of AP, were not increased. Echocar-
diography detected that left ventricular relaxation 
phase was moderately impaired, but there were 
no other pathologies, e.g. no hypertrophy, normal 
regional motility, normal systolic ejection (left 
ventricular ejection fraction — LVEF 58%); no 
significant valvular pathology, normal right heart 
and systolic pulmonary pressure, no pericardial ef-
fusion. A stress-test was interrupted at 80 W/min 
because of moderate AP with corresponding is-
chemic ECG changes (Fig. 2) at a heart rate of 125/ 
/min with sometimes undetectable P waves and 
ST-down-sloping (up to 2.5 mV) in I, II, II, aVF, V5 
and V6 with mild mirror ST-up-sloping in aVR and V1. 
Echocardiography did not detect dyskinesia, the 
left ventricular systolic ejection fraction increased 
from 62% to 73% and the ventricular volume re-
mained unchanged. AP lasted up to 6 min and was 
not relieved by 0.8 mg sublingual nitroglycerin. The 
Figure 1. The resting electrocardiogram shows ischemic ST-changes, in V4–6 and inferior leads.
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woman had typical AP and ischemic ECG changes 
without left dyskinesia and we thought that the 
patient had CSX. Because of the positive family 
history for CHD and the stress-induced ischemic 
ECG changes, the referring physician required 
a ventriculo-coronarography: left ventricular ana-
tomy and function were normal, no flow-liming 
coronary pathology was detected. The patient was 
treated with ranolazine (375 mg b.i.d for 2 weeks 
and afterwards 500 mg b.i.d.) and rosuvastatin 
5 mg/day. After 3 weeks AP was significantly re-
duced (fewer episodes and less intensity of chest 
pain). After 3 months the repolarization changes 
were no longer detectable in the resting ECG. 
A stress-test under therapy with ranolazine 
was interrupted at 150 W because of mild AP at 
a heart rate of 145/min; the ECG showed a –0.2 mV 
ST-down-sloping in V4–5 with ascending morphol-
ogy. In comparison to the first stress-test the 
patient could exercise 3 min longer before mild 
AP occurred and the work load increased by 50 W.
Pathophysiology of ischemia  
and AP in CSX
Etiological heterogeneity and prominent con-
tribution of co-morbidities make understanding the 
pathophysiology of CSX particularly challenging 
[6, 7, 9–16]. It has been, however, established that 
the interplay of multifactorial mechanisms (Table 1) 
may cause myocardial ischemia and AP in patients 
without flow-limiting coronary stenosis, i.e. with 
the so-called normal or non-significant CHD. As 
shown in Table 1, the most important mechanisms 
are endothelial dysfunction (ED), microvascular 
dysfunction (MVD) sometimes with coronary mi-
crovascular spasm, and epicardial coronary artery 
spasm (CAS).
Endothelial dysfunction is a systemic disor-
der which is present in patients with AP with/ 
/without epicardial coronary artery pathology. ED 
results from vascular injury due to arterioscle-
rotic inducing factors, anticipates the angiographic 
documentation of anatomical lesions and has been 
linked with adverse outcomes in many conditions 
Figure 2. A stress-test was interrupted at 80 W/min because of moderate angina pectoris with corresponding ischemic 
changes. The electrocardiogram showed a heart rate of 125/min with sometimes missing P waves and ischemic 
ST-down-sloping (maximal –2.5 mV) in I, II, II, aVF, V5 and V6 with mirror ST-up-sloping in aVR and V1. The echocardio-
graphy did not detect any pathologic changes.
Table 1. Mechanisms of ischemia and angina 
pectoris in cardiac syndrome X.
Endothelial dysfunction is present in the over - 
whel ming majority of cases.
Microvascular dysfunction, in some cases with  
coronary microvascular spasm is also present  
in nearly 50% of cases.
Epicardial coronary artery spam is present in  
about 4% of cases.
All these mechanisms interplay, contribute to micro-
coronary ischemia, reduce collateral perfusion and,  
in the occurrence of a severe coronary flow reduction, 
such after a thrombotic event, limit the reperfusion.
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[16–19]. Known pathophysiologic mechanisms 
related to ED are shown in Table 2. ED is present 
in large majority of CSX-patients, in nearly 50% of 
cases combined with MVD. MVD is defined by low 
coronary reserve, i.e. a dysregulation of coronary 
blood flow, which is not attributable to flow-limiting 
epicardial coronary artery pathology. MVD results 
from either structural or functional mechanisms in 
the microvasculature and induces an inappropriate 
vasodilatation of the coronary microcirculation 
[9, 16–22]. MVD has also been linked with adverse 
outcomes in an increasing number of patholo-
gies [19–23]. Coronary microvascular spasm is 
a dangerous pathophysiologic mechanism which 
has been found in CSX-patients with MVD and 
is linked with poor outcomes [24]. In the WISE 
study, nearly 50% of the women with AP without 
flow-limiting epicardial coronary pathology were 
tested with adenosine and were found to have 
MVD, which was an independent predictor of ad-
verse outcomes [20]. ED and MVD independently 
predict adverse cardiovascular events, such as 
after 5.4-year follow-up occurrence of death, acute 
coronary syndrome (ACS), myocardial infarction, 
stroke, and hospitalization for heart failure [17, 
21–23]. These adverse outcomes are consistent 
with the cardiovascular continuum expected from 
a disorder involving the microvasculature [13, 16, 
17, 21–23]. Many pathologic mechanisms may 
induce CAS which is a proven cause of myocardial 
ischemia and AP [13, 21, 24–30] and is the 3rd 
etiologic mechanism in CSX [13]. CAS is linked 
with some genetic background [9, 10, 23, 24]. In 
CSX-patients CAS has been linked with an ACS in 
> 50% of cases [26, 29, 30] and was thought to be 
the cause of myocardial infarction in some cases 
[24, 30, 31]. In CSX-patients, CAS has been induced 
with acetylcholine (i.e. the parasympathetic sys-
tem) [27], adenosine [22], serotonin, ergonovine, 
histamine and many other less frequently causative 
agents, all of which cause vasodilation when the 
endothelium is intact by releasing nitric oxide [28]. 
Indeed, in the WISE study, CAS could be detected 
in nearly 4% of women without flow-limiting epi-
cardial coronary pathology who were tested with 
acetylcholine [13]. This is the same frequency 
that is found in patients with AP and obstructive 
epicardial coronary artery pathology [26, 27, 29].
Left ventricular wall motion in CSX
In the WISE study, ventriculography data 
showed that resting left ventricular wall motion 
was preserved in CSX-patients [13–15]. Cardiac 
magnetic resonance imaging provides superior 
resolution to evaluate perfusion, and detected 
that CSX-patients had a relative failure to increase 
subendocardial perfusion [13, 14, 27, 28]. In the 
late seventies, our group [32, 33] used pharmaco-
logic stress-testing with either isoproterenol or 
dopamine to assess the effects on left ventricular 
motility in patients with AP with/without flow-
limiting coronary artery pathology.  Kinetocardi-
ography showed that left ventricular dyskinesia 
was induced in nearly 30% of patients without 
flow-limiting coronary pathology, and that the 
dyskinetic changes were similar to those detected 
in patients with epicardial coronary pathology [32, 
33]. Isoproterenol and dobutamine may worsen 
ED and MVD, both frequent in CSX-patients. It is 
thus understandable that CSX-patients report AP 
with concomitant ischemic ECG changes and, if 
the cardiac ischemia is sufficient, dyskinesia may 
occur, as in patients with ischemic due to epicardial 
coronary pathology. Briefly, in CSX symptoms and 
signs of cardiac pathology are the same as those 
of patients with ischemia related to epicardial 
coronary pathology. The difference lies in the fact 
that in CSX the mechanisms of ischemia are mi-
crovascular and flow-limiting epicardial coronary 
pathology is absent.
Defining normal coronary arteries
By visual analysis of biplane CAG coronary 
arteries are often defined normal. However, patho-
logic studies indicate that visual analysis of an-
giographically normal coronary artery segments 
Table 2. Mechanisms involved in endothelial 
dysfunction.
Oxidative stress has several negative effects:
• Increases intracellular superoxide
• Inactivates nitric oxide and formation of  
   peroxynitrite
• Induces nitric oxide synthase uncoupling
• Reduces nitric oxide signaling
• Inhibits prostacyclin formation
• Stimulates endothelin expression
• Inhibits the activity of soluble guanylate cyclase
Increases sympathetic activation and apocrine  
neurohormonal mechanisms:
• Increases production of norepinephrine  
   (also called noradrenalin or levarterenol)
• Increases production of angiotensin II
608 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 6
underestimates the extent of coronary atheroscle-
rosis. Intravascular ultrasound allows high quality 
cross-sectional imaging of the coronary arteries 
in vivo [11, 12] and was used to study angio-
graphically normal coronary reference segments in 
884 patients evaluated for transcatheter therapy 
for symptomatic native epicardial coronary artery 
pathology: only 60 (6.8%) of these angiographically 
normal reference segments were normal [12]. 
Reference segments contained less calcific and 
dense fibrotic plaque and proportionately more 
soft plaque elements. Independent predictors of 
reference segment percent cross-sectional nar-
rowing were male gender, patient age, diabetes 
mellitus, hypercholesterolemia and presence of 
multivessel disease. Independent predictors of 
reference segment calcification were patient age 
and serum creatinine levels. Reference segment 
percent cross-sectional narrowing in 723 patients 
undergoing transcatheter therapy was similar to 
that in patients studied for diagnostic purposes. 
However, reference segment calcification was 
greater in treated patients. Interestingly, reference 
segment disease was not an independent predictor 
of subsequent angiographic restenosis or clini-
cal events within 12 months of follow-up. In the 
WISE study, 100 consecutive women with normal 
coronary arteries were studied by intravascular 
ultrasound and about 80% had atherosclerotic 
plaques [12]. Extrapolating these findings, most of 
48% women in WISE studied who were classified 
as having normal coronary arteries, would probably 
have some coronary plaques [13]. Therefore, when 
using visual analysis of biplane CAG, it would be 
better to speak about non-obstructive epicardial 
coronary pathology rather than saying that coro-
nary arteries are normal.
Epidemiology of CSX
Most CSX-patients are women [4–10, 13–15]. 
There was a strong bias in evaluating women with 
CHD, however, at present coronary angiography is 
rapidly performed in women with suspected CHD. 
It has been now seen that nearly 75% of women 
with typical AP have no flow-limiting epicardial 
coronary pathology [11–15] and depending on dif-
ferent registry data this cardiac situation is also 
found in 5% to 15% of men [10, 13, 16, 21]. It must 
thus be accepted that millions of people (mostly 
women) with AP without flow-limiting coronary 
pathology will probably be identified each year.
Long-term outcomes in CSX
Cardiac syndrome X encompasses different 
pathophysiologic substrates. In spite of an exten-
sive knowledge, we are still uncertain about the 
real outcomes of CSX-patients with stable AP. In 
1940 it was stated that CSX-patients did not have 
an increased high cardiovascular risk, did not re-
quire cardiologic care [3], and to a certain extent, 
that they did not require a general medical care 
[13]. This is not true. As in most diseases, in CSX 
complications are associated with the progression 
of pathology. CXS-patients are not only disabled 
because of persisting symptoms, especially AP, but 
also have serious adverse cardiovascular outcomes 
[8–10, 13, 17, 22–25, 34–36]. It has been suggested 
that in CSX-patients, the prevalence of long-term 
outcomes may be similar to that of asymptomatic 
patients with flow-limiting coronary pathology 
[13, 37] but we lack precise data on long-term 
complications. A statistical method ‘composite 
outcome measures’ is often used to collect data on 
outcomes, but it is proven that the findings may 
obfuscate the data and lead to inaccurate conclu-
sions [38]. To improve the validity of the analysis 
of long-term complications and poor outcomes in 
ACS the ‘weighted composite endpoints’ have been 
used [39]. Unfortunately, up to now, this approach 
has not been used to assess outcomes in CSX and in 
other clinical aspects of CHD. Thus, at present we 
know that CSX is not a benign condition as previ-
ously believed but we ignore the exact frequency 
of long-term complications in this pathology. Also, 
we cannot accurately compare the prevalence of 
cardiovascular outcomes between CSX-patients 
and patients with flow-limiting epicardial coronary 
artery pathology.
Causes of severe outcomes in CSX
By definition, in CSX myocardial ischemia and 
AP are not due to flow-limiting coronary pathology. 
As shown in Table 3, different complex microc-
oronary pathophysiologic substrates are present 
in CSX and are linked with adverse long-term 
cardiovascular complications [8–10, 13, 17, 22, 
24, 34–36]. In CSX, most serious adverse events 
result from coronary thrombosis, which is usually 
associated with rupture or erosion of vulnerable 
plaques, usually not detected by conventional 
CAG [11–13, 40]. Gender and age are important in 
patients with ACS or myocardial infarction without 
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flow-limiting coronary pathology. Female sex and 
younger age are independent predictors. These 
complications are detected in 10–25% of women 
and only in 6–10% of men [13, 31]. In CXS-patients 
with sudden coronary death, the most frequent 
cause was plaque rupture, in a third of cases ero-
sion and in the rest several causes were detected, 
such as calcified nodules [13, 37]. Patient gender 
and age are important, because plaque rupture was 
the cause of death in nearly one third of women, 
but in less than one sixth of men. Acute cardiac 
thrombi were the predominant cause in women 
< 50-year but plaque rupture was the predominant 
cause in > 50-year-old women. In men, age did not 
play any role in the occurrence of plaque rupture. 
Of course, in CSX the presence of ED, MVD and 
sometimes CAS interplays with the plaque erosion 
or rupture and worsens the outcomes [13, 37, 40]. In 
CSX, most serious adverse events result from coro-
nary thrombosis which is usually associated with 
rupture or erosion of vulnerable plaques, an event 
which commonly is not detected by conventional 
CAG [23–25, 37, 40]. In CXS-patients with sudden 
death plaque, rupture was the most frequent cause 
(in more than 30% of cases) while in the rest several 
causes, e.g. calcified nodules, were detected and 
there is a patient gender difference, because plaque 
rupture was the cause of death in about one third 
of women, but in less than one sixth of men [11, 
36–38]. Patient age is also relevant in CSX. Indeed, 
in < 50-year-old women acute cardiac thrombi 
were the predominant cause. On the other hand, in 
> 50-year-old women plaque rupture was the pre-
dominant cause. Interestingly, age did not play any 
role in the occurrence of plaque rupture in men [11, 
24, 36–38]. Of course, in CSX the presence of ED, 
MVD and sometimes CAS interplays with the plaque 
erosion or rupture and worsens the outcomes.
Therapy of CSX
Obviously, cardiac revascularization is not 
a therapeutic option in CSX. We lack specific drugs 
for treating CSX. Therapy is empirical and drugs 
used in CHD are also used in CSX. Low-dose as-
pirin is largely used, even if there is no evidence 
that long-term aspirin should be given to patients 
even with known cardiovascular disease: theoretical 
arguments that aspirin can prevent cardiovascular 
events by reducing the propagation of thrombus 
are countered by evidence that plaque hemorrhage 
from vasa vasorum may also cause plaque growth 
instability; aspirin may also detract from the benefits 
of angiotensin-converting enzyme inhibitors [41]. 
We lack controlled studies on statins (or HMG-CoA 
reductase inhibitors) in the therapy of CSX but 
these drugs are used to treat endothelial dysfunc-
tion. An experimental study [42] has proven that 
pravastatin reverses obesity-induced dysfunction 
of pluripotent stem-cells derived from endothe-
lial cells via a nitric oxide-dependent mechanism. 
Similar data are not available for other statins. It is 
possible that statins may improve ED also in CSX. 
Short-acting sublingual or spray aspirin or isosorb-
ide nitrates are largely used to treat AP in CSX, 
but in this pathology this therapy is less effective 
than in patients with CHD. Beta-blockers, calcium 
antagonists, and long-acting nitrates or nicorandil 
are often used to treat AP in CSX. However, beta-
-blockers are usually less effective than in CHD. 
Nitrates and nicorandil are also less effective and 
induce more adverse effects than in CHD. A study 
in patients with stable vasospastic angina has shown 
that, when compared with calcium antagonists, 
nitrates did not improve prognosis, and on the 
contrary, the combined therapy increased the risk 
for cardiac adverse events, especially when trans-
dermal nitroglycerin and nicorandil were used [43]. 
Table 3. Pathophysiology of serious cardiac out-
comes in cardiac syndrome X.
Most adverse serious events, such as acute coro-
nary syndrome and myocardial infarction result 
from coronary thrombosis. These events are usually 
associated with rupture or erosion of vulnerable 
plaques, usually not detected by conventional  
coronarography.
In patients with sudden coronary death, the most 
frequent cause (in a third of cases) is plaque rupture 
due to erosion. In the rest of cases, several causes 
were detected, such as calcified nodules.
Patient gender and age are important. Plaque rup-
ture was the cause of death in about one third of 
women, but in less than one sixth of men. Acute 
cardiac thrombi were the predominant cause in 
women < 50-year; on the other hand, plaque rup-
ture was the predominant cause in > 50-year-old 
women. In men, age did not play any role in the  
occurrence of plaque rupture.
In nearly 95% of cases, the pathophysiologic mecha-
nisms are endothelial dysfunction, microvascular 
dysfunction (sometimes with coronary microvascu-
lar spasm). Epicardial coronary artery spasm occurs 
in nearly 4% of cases.
These mechanisms interplay with the plaque ero-
sion or rupture and induce cardiovascular poor 
outcomes. As in other arteriosclerotic conditions, 
plaque rupture or erosion, coagulation dysfunction, 
several products of inflammation etc. may cause 
acute thrombosis and severe cardiac events.
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Ranolazine is frequently off-label used in CSX [44, 
45]. We lack controlled studies in CSX but many 
cardiologists report a better efficacy in reducing AP 
than with beta-blockers, calcium antagonists, and 
long-acting nitrates or nicorandil.
Conclusions
Coronary heart disease represents an im-
portant clinical problem worldwide. The number 
of cardiac interventions is expected to increase 
over the coming decades. In the past, there was 
a strong bias in evaluating women with CHD. 
However, at present, more women than men are 
evaluated for CHD and it has been recognized 
that the prevalence of CHD in women is at least 
the same as in men. We have learned that CSX is 
frequent because worldwide each year millions 
of people (mostly women) with AP without flow-
limiting epicardial coronary pathology are identi-
fied. Indeed, in nearly 75% of women and in up to 
15% of men with typical AP coronary angiography 
does not detect flow-limiting epicardial coronary 
pathology. Also, data from large myocardial infarc-
tion registries suggest a 5% to 25% prevalence 
of cases without flow-limiting coronary pathology 
[23]. It must be considered that these people are 
said to have normal coronary arteries by visual 
analysis of biplane CAG. However, as demonstrated 
from autopsy and in vivo by ultrasound intravas-
cular studies it would be more appropriate to say 
that in the majority of cases CAG does not detect 
obstructive or flow-limiting coronary pathology. ED 
and MVD (sometimes also coronary microvascular 
spasm and epicardial CAS) are established coronary 
pathophysiologic substrates in CSX. Symptoms and 
signs of cardiac pathology are the same as those of 
patients with flow-limiting coronary pathology. The 
difference lies in the fact that in CSX the mecha-
nisms of myocardial ischemia are microvascular 
and flow-limiting epicardial coronary pathology is 
absent. The pathologic entities at work in CSX by 
interplay are linked with poor long-term outcomes, 
specifically hospitalization, ACS, myocardial in-
farction, coronary revascularization and sudden 
death. The prevalence of these outcomes is prob-
ably smaller than in patients with CHD but we 
lack precise data. Given the association between 
CSX and consequent downstream morbidity, it 
seems logical to assess long-term outcomes by 
appropriate analysis, e.g. by the ‘weighted com-
posite endpoints’ approach. Nonetheless, severe 
cardiovascular complications are frequent in CSX 
and thus CSX is not a benign condition. Drugs used 
in CHD are prescribed in the therapy of CSX, but 
we lack data from specific double-blind randomized 
trials. It seems that statins and ranolazine might 
exert positive effects. However, specific research 
to target interventions in CSX would be necessary.
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